{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:18:51Z","timestamp":1778501931521,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.clinbiochem.2016.04.011","type":"journal-article","created":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T17:26:35Z","timestamp":1461950795000},"page":"1390-1395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Sampling on ice will not yield reliable uric acid monitoring in rasburicase-treated patients"],"prefix":"10.1016","volume":"49","author":[{"given":"Barbara","family":"Depreter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronique","family":"Stove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5702-6792","authenticated-orcid":false,"given":"Joris","family":"Delanghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0005","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2141.2010.08143.x","article-title":"Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus","volume":"149","author":"Cairo","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3324\/haematol.12327","article-title":"Tumor lysis syndrome: current perspective","volume":"93","author":"Hochberg","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0015","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/08998280.2005.11928082","article-title":"Rasburicase (Elitek): a novel agent for tumor lysis syndrome","volume":"18","author":"Ueng","year":"2005","journal-title":"Proc. (Baylor Univ. Med. Cent.)"},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0020","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1345\/aph.1C336","article-title":"Rasburicase for the treatment and prevention of hyperuricemia","volume":"37","author":"Yim","year":"2003","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0025","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jbspin.2012.01.004","article-title":"Therapeutic perspectives on uricases for gout","volume":"79","author":"Garay","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.7150\/ijms.4.83","article-title":"Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout","volume":"4","author":"Cammalleri","year":"2007","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0035","first-page":"890","article-title":"Enzymatic uricolysis: a study of the effect of a fungal urate-oxydase","volume":"17","author":"Brogard","year":"1972","journal-title":"Rev. Eur. Etud. Clin. Biol."},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0040","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1200\/JCO.2003.04.115","article-title":"Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1","volume":"21","author":"Coiffier","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0045","first-page":"96","volume":"44","author":"Rasburicase (elitek) for hyperuricemia","year":"2002","journal-title":"Med. Lett. Drugs Ther."},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0050","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/sj.leu.2403566","article-title":"Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial","volume":"19","author":"Jeha","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0055","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1093\/annonc\/mdr490","article-title":"A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome","volume":"23","author":"Vadhan-Raj","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0060","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.leukres.2004.09.004","article-title":"A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy","volume":"29","author":"Liu","year":"2005","journal-title":"Leuk. Res."},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0065","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1592\/phco.26.6.806","article-title":"Single-dose rasburicase 6mg in the management of tumor lysis syndrome in adults","volume":"26","author":"McDonnell","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0070","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1592\/phco.28.6.685","article-title":"Evaluation of a single fixed dose of rasburicase 7.5mg for the treatment of hyperuricemia in adults with cancer","volume":"28","author":"Reeves","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0075","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/bmt.2010.212","article-title":"Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies","volume":"46","author":"Trifilio","year":"2011","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0080","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1182\/blood.V97.10.2998","article-title":"A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis","volume":"97","author":"Goldman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0085","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F","article-title":"International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop","volume":"42","author":"Wilson","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0090","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1515\/cclm-2012-0300","article-title":"Refrigeration is not necessary for measurement of uric acid in patients treated with rasburicase","volume":"51","author":"Lindeman","year":"2013","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0095","unstructured":"Roche Uric acid UA2, package insert 2014\u2013(03,V6.2)."},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0100","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1600-0609.2007.01013.x","article-title":"Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase","volume":"80","author":"Hummel","year":"2008","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0105","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0009-9120(89)80008-6","article-title":"Activation energy and lectin affinity chromatography of gamma-glutamyltransferase as a marker for enzyme heterogeneity","volume":"22","author":"Delanghe","year":"1989","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0110","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0003-2697(02)00293-2","article-title":"A colorimetric 96-well microtiter plate assay for the determination of urate oxidase activity and its kinetic parameters","volume":"309","author":"Fraisse","year":"2002","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0115","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0301-4622(94)00150-I","article-title":"Study of pH and temperature-induced transitions in urate oxidase (Uox-EC1.7.3.3) by microcalorimetry (DSC), size exclusion chromatography (SEC) and enzymatic activity experiments","volume":"54","author":"Bayol","year":"1995","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0120","first-page":"633","article-title":"The catalytic activity and activation-energy of Creatine-kinase isoenzymes","volume":"20","author":"Hagelauer","year":"1982","journal-title":"J. Clin. Chem. Clin. Biochem."},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0125","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1200\/JCO.2003.04.115","volume":"21","author":"Coiffier","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0130","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/sj.bmt.1705379","article-title":"Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia","volume":"37","author":"Trifilio","year":"2006","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0135","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1373\/49.8.1417","article-title":"Sample preparation in patients receiving uric acid oxidase (rasburicase) therapy","volume":"49","author":"Lim","year":"2003","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0140","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2001.19.3.697","article-title":"Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma","volume":"19","author":"Pui","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0145","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/00365519950185229","article-title":"Current databases on biological variation: pros, cons and progress","volume":"59","author":"Ricos","year":"1999","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.clinbiochem.2016.04.011_bb0150","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1373\/clinchem.2006.081414","article-title":"Perchloric acid treatment to stabilize uric acid concentrations in blood samples of patients receiving uric acid oxidase (rasburicase) therapy","volume":"53","author":"Stove","year":"2007","journal-title":"Clin. Chem."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000991201630042X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000991201630042X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:49:49Z","timestamp":1757864989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000991201630042X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":30,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S000991201630042X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2016.04.011","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sampling on ice will not yield reliable uric acid monitoring in rasburicase-treated patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2016.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}